Leading Medical Experts to Discuss Promising Developments on Prescription Digital Therapeutics and Nutritional Cognitive Behavioral Therapy for Type 2 Diabetes Patients
SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced a virtual educational webinar symposium featuring a panel of medical and technology experts to discuss the use of nCBT delivered via prescription digital therapeutics to combat the underlying causes of cardiometabolic diseases like type 2 diabetes. This presentation will focus on the recently revised American Diabetes Association (ADA) Standard of Care guidelines which recommend digital support tools as part of a therapy regimen.
WHEN: Wednesday, June 1, 2022 – 12:00 – 1:00 p.m. ET
WHAT: The online symposium will convene a panel of experts to review the new ADA behavioral therapy guidelines while looking at how nCBT works to support behavioral change in patients with cardiometabolic diseases. Additionally, it will showcase how PDT can offer a unique mechanism of action that enables nCBT to be used at scale.
The panel will review and discuss recently released clinical trial data from Better Therapeutics’ pivotal clinical trial for BT-001, its digital therapeutic platform for type 2 diabetes. Released earlier this year, the clinical trial demonstrated significant reduction in A1c levels that surpassed results seen in patients using pharmaceutical solutions alone.
The symposium will also discuss the future potential for prescription digital therapeutics to address the ADA’s behavior change guidelines and to improve type 2 diabetes patient outcomes.
WHO:
Panel Chair
- Marc Bonaca, MD, MPH, Professor of Medicine and Director of Vascular Research, University of Colorado
Moderators
- Bob Eckel, MD, Professor of Medicine, University of Colorado and past president of American Heart Association and American Diabetes Association
- Judy Hsia, MD, Research Professor of Medicine, University of Colorado
Panel and Presenters:
- Hayden Bosworth, PhD, Research Professor, Department of Medicine, Division of General Internal Medicine, Department of Psychiatry and Behavioral Sciences, School of Nursing, Duke University Medical Center
- Amy Bucher, PhD, Chief Behavioral Officer, Lirio
- Prapti Mehta, MD, Private Practice Psychiatrist, San Francisco, California
- Kristin Wynholds, Chief Product Officer, Better Therapeutics
WHERE: To attend the webinar, please register at: bit.ly/3wpwBWA
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding the timing and results of the ongoing trial of BT-001 in patients with type 2 diabetes, Better Therapeutics’ plans regarding FDA submissions, expectations related to the potential benefits of BT-001 and CBT and their potential treatment applications, Better Therapeutics’ plans regarding the research and advancement of its product candidates for additional treatments, expectations related to the interest of healthcare providers and payers in PDTs and legislative developments affecting PDTs and the outcome of such developments, among others. These forward-looking statements are based on the current expectations of the management of Better Therapeutics and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ business, such as the willingness of the FDA to authorize PDTs for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates and other risks and uncertainties included under the header “Risk Factors” in the definitive proxy statement/prospectus filed by us on October 12, 2021.
Contacts
Peter Duckler at Real Chemistry
